复方泛影葡胺注射液消化道给药的安全性观察  

Alimentary canal administration of compound meglumine diatrizoate injection: observation of its safety

作　　者：姜敏霞[1] 张学勇[1] 华俊彦 JIANG Minxia;ZHANG Xueyong;HUA Junyan(Department of Radiology,Lishui Municipal People＇s Hospital,Lishui,Zhejiang Province 323000,China)

机构地区：[1]丽水市人民医院放射科,浙江323000

出　　处：《介入放射学杂志》2018年第10期975-978,共4页Journal of Interventional Radiology

基　　金：浙江省丽水市科技计划项目(2012ZC039)

摘　　要：目的了解复方泛影葡胺注射液口服或通过胃管注入消化道时的安全性。方法对2016年1月—2017年12月丽水市人民医院742例选择复方泛影葡胺注射液消化道给药用于消化道造影或肠梗阻润肠通便治疗的住院患者,观察用药后住院期间不良反应发生情况,统计其轻度、中度、重度不良反应的发生率。结果 742例患者中,704例无其它药物或食物过敏史,38例有过敏史。前者发生轻度、中度不良反应分别为2例和5例,不良反应发生率分别为0.28%和0.71%,除1例轻度不良反应为一过性腹痛,其余6例均为过敏反应;后者发生中度不良反应2例,发生率为5.26%,均为过敏反应;两者不良反应发生率差异无统计学意义(P=0.114)。所有病例都未出现重度不良反应。结论复方泛影葡胺注射液消化道给药时不良反应发生率明显低于文献报道经血管给药时不良反应的发生率,消化道给药有较高安全性。Objective To evaluate the safety of administration of compound meglumine diatrizoate injection through oral taking or through gastric tube. Methods The clinical data of a total of 742 inpatients, who received alimentary canal administration of compound meglumine diatrizoate injection for digestive tract angiography or for relaxing bowel in patients with intestinal obstruction during the period from January 2016 to December 2017 at Lishui Municipal People＇s Hospital, Zhejiang Province, China, were retrospectively analyzed. The adverse reactions occurring in hospitalization period after medication were recorded, and according to the severity of adverse reactions （mild, moderate and severe） the results were statistically analyzed. Results Of the 742 patients, 704 had no history of allergy to other drugs or foods and 38 had allergic history. Mild and moderate adverse reactions occurred in 2 and 5 patients respectively in the former 704 patients, with the adverse reaction rates being 0.28% and 0.71% respectively; except one patient, whose adverse reaction presented as transient abdominal pain, all the other 6 patients showed allergic reaction. Of the latter 38 patients who had allergic history, moderate adverse reaction occurred in 2 patients, with an adverse reaction rate of 5.26%, and both the 2 patients showed allergic reaction. No statistically significant difference in the adverse reaction rate existed between the two groups （P=0.114）. No severe adverse reactions occurred in all patients. Conclusion The results of this study indicate that the adverse reaction rate caused by alimentary canal administration of compound meglumine diatrizoate injection is obviously lower than that caused by transvascular administration of compound meglumine diatrizoate injection reported in the literature. Therefore, alimentary canal administration of compound meglumine diatrizoate injection carries higher safety.

关 键 词：泛影葡胺 消化道造影 肠梗阻 不良反应 

分 类 号：R445.2[医药卫生—影像医学与核医学]